Skip to main content

October 20, 2023
Symposium Schedule

Time Event
7:00 - 7:30 a.m.

Breakfast

A Treatment Option for the Polyneuropathy of hATTR Amyloidosis
Marcus Anthony Urey, MD
Alnylam Product Theater - NON CME

8:00 a.m. Opening Remarks
Session 1

ATTR Amyloidosis

Chairs James Fang, MD; Mathew Maurer, MD
8:10 a.m. Clinical Presentation of TTR
Spencer Carter, MD
University of Utah, Salt Lake City, Utah
8:35 a.m. Stabilizers and Silencers
Jose N. Nativi-Nicolau, MD
Mayo Clinic, Jacksonville, Florida
9:00 a.m.  Neurological Presentations in Amyloidosis
Kelsey Barrell, MD
University of Utah, Salt Lake City, Utah
9:25 a.m.

The Quest for Improving Quality of Life For Those With Amyloidosis
Isabelle Lousada
Amyloidosis Research Consortium, Newton, Massachusetts 

9:50 a.m.

Break

Session 2

AL Amyloidosis

Chairs Josephine Abraham, MD, MPH; Ramiro Garzon, MD
10:20 a.m.

Clinical Presentation and Review of Current and Novel Diagnostic Strategies
Anita D'Souza, MD
Medical College of Wisconsin, Milwaukee, Wisconsin

10:45 a.m.

Treatment Paradigms for AL Amyloidosis: Newly Diagnosed
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM
University College London, London, United Kingdom

11:10 a.m.

Treatment Paradigms for AL Amyloidosis: Relapsed/Refractory 
Raymond Comenzo, MD
Tufts Medical Center, Boston, Massachusetts

11:35 a.m.

Improving Organ Function and Recovery: Depth of Response and Anti-Fibril Strategies
Amandeep Godara, MBBS
University of Utah, Salt Lake City, Utah

12:00 p.m.

Lunch

Session 3

Keynote Address

Chairs Spencer Carter, MD; Jose N. Nativi-Nicolau, MD
1:00 p.m.

Cardiology Grand Rounds 
Mathew Maurer, MD
NY Presbyterian / Columbia University, New York, New York

Keynote Address: The Future of Amyloidosis Therapy

1:50 p.m. Role of Imaging in Amyloidosis
Ahmad Masri, MD, MS
Oregon Health and Science University, Portland, Oregon
2:15 p.m.

AI Approaches to Identifying Patients At Risk of Amyloidosis
Julie Lynch, PhD, RN, MBA
George E. Wahlen VA, Salt Lake City, Utah

2:40 p.m.

Optimizing Clinical and Research Flow in an Amyloidosis Referral Program
Jill Waldron, APRN
University of Utah, Salt Lake City, Utah

3:05 p.m. Break
Session 4

The Great Debates

Chairs Amandeep Godara, MBBS; Josef Stehlik, MD, MPH
3:30 p.m.

PRO: We should screen patients with ortho manifestations for TTR amyloidosis
Jose N. Nativi-Nicolau, MD
Mayo Clinic, Jacksonville, Florida

3:45 p.m. CON: We should screen patients with ortho manifestations for TTR amyloidosis
Ahmad Masri, MD, MS
Oregon Health and Science University, Portland, Oregon
4:00 p.m. Discussion
4:15 p.m. PRO: Role of upfront stem cell transplant in AL amyloidosis
Anita D'Souza, MD
Medical College of Wisconsin, Milwaukee, Wisconsin
4:30 p.m. CON: Role of upfront stem cell transplant in AL amyloidosis
Tibor Kovacsovics, MD
City of Hope Phoenix, Phoenix, Arizona
4:45 p.m. Discussion
5:00 p.m. Closing Remarks
5:30 p.m.

Symposium Dinner Presentation - Salt Lake City Marriott University Park
Dr. Laurence Parker
University of Utah, Salt Lake City, Utah

The Journey Through Diagnosis and Treatment: From a Patient's Perspective